‘New vaccine promises better protection against cancer’

Staff Reporter

NEW DELHI: GlaxoSmithKline Pharmaceuticals (GSK) has released the results of clinical studies conducted for its latest cervical cancer vaccine Cervarix which it claims will offer its users protection against five of the most common cancer-causing viruses and give higher immunity compared to the other available vaccines.

The company’s vice-president (South Asia) Hasit Joshipura said: “We are pleased with the new findings which confirm the importance of the role of Cervarix in helping protect women against cervical cancer.”


He said the studies confirmed that the new vaccine is not only highly effective at protecting against the two most common cervical cancer-causing human papillomavirus (HPV) types, 16 and 18, but also provides additional cross-protection against HPV types 31, 33 and 45, the three most common cancer-causing virus types.

Prof. Neerja Bhatla of the All-India Institute of Medical Sciences Department of Obstetrics and Gynaecology said “these results amply demonstrate that preventive vaccination is one of the most effective methods of primary prevention of HPV infection. In tandem with screening tests, it is perfectly positioned to lend a decisive edge against this deadly cancer. Extending the scope of protection beyond types 16 and 18 will allow prevention of the vast majority of cases of cervical cancer in India. Preventive vaccination against cervical cancer has now come of age”.

Recommended for you